Poxel SA | MedPath

Robust Pipeline of 80+ Therapies Advancing for Chronic Kidney Disease Treatment in 2025

2 months ago

• DelveInsight's 2025 report reveals a robust pipeline with 75+ companies developing 80+ therapies for chronic kidney disease, highlighting significant industry investment in addressing this growing health concern. • Key late-stage candidates include AstraZeneca's Baxdrostat and Novo Nordisk's Ziltivekimab, targeting different pathways in CKD progression with promising clinical results. • Multiple novel mechanisms are being explored across all development stages, including aldosterone synthase inhibition, anti-inflammatory approaches, and soluble guanylate cyclase activation, expanding potential treatment options.

NASH Pipeline Shows Promise with 80+ Emerging Therapies in Development

2 months ago

• Over 80 companies are actively developing treatments for Non-Alcoholic Steatohepatitis (NASH), with Inventiva Pharma and Cirius Therapeutics leading with Phase III candidates lanifibranor and MSDC-0602K respectively. • Lanifibranor, a triple PPAR agonist with FDA Breakthrough Therapy designation, demonstrates significant anti-inflammatory and antifibrotic properties, while MSDC-0602K selectively modulates the mitochondrial pyruvate carrier to improve metabolic parameters. • Novel therapeutic approaches include Terns Pharmaceuticals' THR-β agonist TERN-501 and HighTide Biopharma's HTD1801, both showing promising results in reducing liver fat and improving metabolic markers in Phase II trials.

NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies

6 months ago

• The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. • This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes. • Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape. • The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.

Adrenoleukodystrophy: Emerging Therapies Show Promise in Clinical Trials

8 months ago

• Multiple companies are developing novel therapies for Adrenoleukodystrophy (ALD), a rare genetic disorder affecting the adrenal glands and nervous system. • Key emerging therapies include ABX-002 (Autobahn Therapeutics), VK0214 (Viking Therapeutics), and SBT101 (SwanBio Therapeutics), among others, targeting various aspects of the disease. • Leriglitazone (MIN102) by Minoryx Therapeutics faced a setback with a negative CHMP opinion, but a re-examination for conditional approval is planned. • Clinical trials are exploring different routes of administration, including intravenous, subcutaneous, and oral, with diverse molecule types such as monoclonal antibodies and small molecules.